We identified a panel of markers altered by tobacco carcinogens and inversely affected by prostacyclin, including <i>PPAR</i>γ, <i>15PGDH, CES1, COX-2, ECADHERIN, SNAIL, VIMENTIN, CRB3, MIR34c, and MIR221</i> These data introduce a panel of potential markers for monitoring interception of bronchial dysplasia progression during chemoprevention with prostacyclin.